Skip to content
The Policy VaultThe Policy Vault

Caprelsa (vandetanib) — Medica

Thyroid carcinoma, medullary

Initial criteria

  • Patient is age ≥ 18 years

Reauthorization criteria

  • Patient continues to meet initial criteria

Approval duration

1 year